Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma

Giuseppe Palmieri, Sabrina M R Satriano, Mario Budroni, Antonio Cossu, Francesco Tanda, Sergio Canzanella, Corrado Caracò, Ester Simeone, Antonio Daponte, Nicola Mozzillo, Giuseppe Comella, Giuseppe Castello, Paolo A. Ascierto

Research output: Contribution to journalArticle

Abstract

Background: Detection of circulating malignant cells (CMCs) through a reverse transcriptase-polymerase chain reaction (RT-PCR) assay seems to be a demonstration of systemic disease. We here evaluated the prognostic role of RT-PCR assays in serially-taken peripheral blood samples from patients with malignant melanoma (MM). Methods: One hundred forty-nine melanoma patients with disease stage ranging from I to III were consecutively collected in 1997. A multi-marker RT-PCR assay was used on peripheral blood samples obtained at time of diagnosis and every 6 months during the first two years of follow-up (total: 5 samples). Univariate and multivariate analyses were performed after 83 months of median follow-up. Results: Detection of at least one circulating mRNA marker was considered a signal of the presence of CMC (referred to as PCR-positive assay). A significant correlation was found between the rate of recurrences and the increasing number of PCR-positive assays (P = 0.007). Presence of CMC in a high number (≥2) of analysed blood samples was significantly correlated with a poor clinical outcome (disease-free survival: P = 0.019; overall survival: P = 0.034). Multivariate analysis revealed that presence of a PCR-positive status does play a role as independent prognostic factors for overall survival in melanoma patients, adding precision to the predictive power of the disease stage. Conclusion: Our findings indicated that serial RT-PCR assay may identify a high risk subset of melanoma patients with occult cancer cells constantly detected in blood circulation. Prolonged presence of CMCs seems to act as a surrogate marker of disease progression or a sign of more aggressive disease.

Original languageEnglish
Article number266
JournalBMC Cancer
Volume6
DOIs
Publication statusPublished - Nov 15 2006

Fingerprint

Circulating Neoplastic Cells
Reverse Transcriptase Polymerase Chain Reaction
Melanoma
Polymerase Chain Reaction
Multivariate Analysis
Survival
Blood Circulation
Disease-Free Survival
Disease Progression
Biomarkers
Recurrence
Messenger RNA
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma. / Palmieri, Giuseppe; Satriano, Sabrina M R; Budroni, Mario; Cossu, Antonio; Tanda, Francesco; Canzanella, Sergio; Caracò, Corrado; Simeone, Ester; Daponte, Antonio; Mozzillo, Nicola; Comella, Giuseppe; Castello, Giuseppe; Ascierto, Paolo A.

In: BMC Cancer, Vol. 6, 266, 15.11.2006.

Research output: Contribution to journalArticle

Palmieri, Giuseppe ; Satriano, Sabrina M R ; Budroni, Mario ; Cossu, Antonio ; Tanda, Francesco ; Canzanella, Sergio ; Caracò, Corrado ; Simeone, Ester ; Daponte, Antonio ; Mozzillo, Nicola ; Comella, Giuseppe ; Castello, Giuseppe ; Ascierto, Paolo A. / Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma. In: BMC Cancer. 2006 ; Vol. 6.
@article{26fdbd14b91b4fb085b2e903cfdfcddf,
title = "Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma",
abstract = "Background: Detection of circulating malignant cells (CMCs) through a reverse transcriptase-polymerase chain reaction (RT-PCR) assay seems to be a demonstration of systemic disease. We here evaluated the prognostic role of RT-PCR assays in serially-taken peripheral blood samples from patients with malignant melanoma (MM). Methods: One hundred forty-nine melanoma patients with disease stage ranging from I to III were consecutively collected in 1997. A multi-marker RT-PCR assay was used on peripheral blood samples obtained at time of diagnosis and every 6 months during the first two years of follow-up (total: 5 samples). Univariate and multivariate analyses were performed after 83 months of median follow-up. Results: Detection of at least one circulating mRNA marker was considered a signal of the presence of CMC (referred to as PCR-positive assay). A significant correlation was found between the rate of recurrences and the increasing number of PCR-positive assays (P = 0.007). Presence of CMC in a high number (≥2) of analysed blood samples was significantly correlated with a poor clinical outcome (disease-free survival: P = 0.019; overall survival: P = 0.034). Multivariate analysis revealed that presence of a PCR-positive status does play a role as independent prognostic factors for overall survival in melanoma patients, adding precision to the predictive power of the disease stage. Conclusion: Our findings indicated that serial RT-PCR assay may identify a high risk subset of melanoma patients with occult cancer cells constantly detected in blood circulation. Prolonged presence of CMCs seems to act as a surrogate marker of disease progression or a sign of more aggressive disease.",
author = "Giuseppe Palmieri and Satriano, {Sabrina M R} and Mario Budroni and Antonio Cossu and Francesco Tanda and Sergio Canzanella and Corrado Carac{\`o} and Ester Simeone and Antonio Daponte and Nicola Mozzillo and Giuseppe Comella and Giuseppe Castello and Ascierto, {Paolo A.}",
year = "2006",
month = "11",
day = "15",
doi = "10.1186/1471-2407-6-266",
language = "English",
volume = "6",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma

AU - Palmieri, Giuseppe

AU - Satriano, Sabrina M R

AU - Budroni, Mario

AU - Cossu, Antonio

AU - Tanda, Francesco

AU - Canzanella, Sergio

AU - Caracò, Corrado

AU - Simeone, Ester

AU - Daponte, Antonio

AU - Mozzillo, Nicola

AU - Comella, Giuseppe

AU - Castello, Giuseppe

AU - Ascierto, Paolo A.

PY - 2006/11/15

Y1 - 2006/11/15

N2 - Background: Detection of circulating malignant cells (CMCs) through a reverse transcriptase-polymerase chain reaction (RT-PCR) assay seems to be a demonstration of systemic disease. We here evaluated the prognostic role of RT-PCR assays in serially-taken peripheral blood samples from patients with malignant melanoma (MM). Methods: One hundred forty-nine melanoma patients with disease stage ranging from I to III were consecutively collected in 1997. A multi-marker RT-PCR assay was used on peripheral blood samples obtained at time of diagnosis and every 6 months during the first two years of follow-up (total: 5 samples). Univariate and multivariate analyses were performed after 83 months of median follow-up. Results: Detection of at least one circulating mRNA marker was considered a signal of the presence of CMC (referred to as PCR-positive assay). A significant correlation was found between the rate of recurrences and the increasing number of PCR-positive assays (P = 0.007). Presence of CMC in a high number (≥2) of analysed blood samples was significantly correlated with a poor clinical outcome (disease-free survival: P = 0.019; overall survival: P = 0.034). Multivariate analysis revealed that presence of a PCR-positive status does play a role as independent prognostic factors for overall survival in melanoma patients, adding precision to the predictive power of the disease stage. Conclusion: Our findings indicated that serial RT-PCR assay may identify a high risk subset of melanoma patients with occult cancer cells constantly detected in blood circulation. Prolonged presence of CMCs seems to act as a surrogate marker of disease progression or a sign of more aggressive disease.

AB - Background: Detection of circulating malignant cells (CMCs) through a reverse transcriptase-polymerase chain reaction (RT-PCR) assay seems to be a demonstration of systemic disease. We here evaluated the prognostic role of RT-PCR assays in serially-taken peripheral blood samples from patients with malignant melanoma (MM). Methods: One hundred forty-nine melanoma patients with disease stage ranging from I to III were consecutively collected in 1997. A multi-marker RT-PCR assay was used on peripheral blood samples obtained at time of diagnosis and every 6 months during the first two years of follow-up (total: 5 samples). Univariate and multivariate analyses were performed after 83 months of median follow-up. Results: Detection of at least one circulating mRNA marker was considered a signal of the presence of CMC (referred to as PCR-positive assay). A significant correlation was found between the rate of recurrences and the increasing number of PCR-positive assays (P = 0.007). Presence of CMC in a high number (≥2) of analysed blood samples was significantly correlated with a poor clinical outcome (disease-free survival: P = 0.019; overall survival: P = 0.034). Multivariate analysis revealed that presence of a PCR-positive status does play a role as independent prognostic factors for overall survival in melanoma patients, adding precision to the predictive power of the disease stage. Conclusion: Our findings indicated that serial RT-PCR assay may identify a high risk subset of melanoma patients with occult cancer cells constantly detected in blood circulation. Prolonged presence of CMCs seems to act as a surrogate marker of disease progression or a sign of more aggressive disease.

UR - http://www.scopus.com/inward/record.url?scp=33751401113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751401113&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-6-266

DO - 10.1186/1471-2407-6-266

M3 - Article

C2 - 17107608

AN - SCOPUS:33751401113

VL - 6

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 266

ER -